Haemoglobin-based oxygen carriers

Bibliography

• WINSLOW RM: New transfusion strategies: red cell substitutes. Ann. Rev. Med. (1999) 50:337-353. Comprehensive review of the blood-substitute field.
   Google Scholar
• TSUCHIDA E, TAKEOKA S: Stabilized hemoglobin vesicles. In: Artificial Red Cells. Tsuchida E (Ed.), John Wiley & Sons, New York, USA (1995):35–64.
   Google Scholar
• RUDOLPH AS: Encapsulation of hemoglobin inlip osomes. In: Blood Substitutes: Physiological Basis of Efficacy Winslow RM, Vandegriff KD, Intaglietta M (Eds.), Birkhauser, Boston, USA (1995):90–104.
   Google Scholar
• WINSLOW RM: Blood substitutes. Adv. Drug Del. Rev.(2000) 40:131–142.
   PubMed Web of Science ®Google Scholar
• Hemoglobin-based Red Cell Substitutes. Winslow RM(Ed.), Johns Hopkins University Press, Baltimore, USA (1992).
   Google Scholar
• •Comprehensive monologue on the subject of haemoglobin-based oxygen carriers, with early assumptions about molecular design.
   Google Scholar
• CHRISTENSEN SM, MEDINA F, WINSLOW RW, SNELL SM,ZEGNA A, MARINI MA: Preparation of human hemoglobin Ao for possible use as a blood substitute. J. Biochem. Biophys. Meth. (1988) 17:143–154.
   PubMedGoogle Scholar
• D'AGNILLO F, CHANG TMS: Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties. Nature Biotech. (1998) 16 :667–671.
   PubMed Web of Science ®Google Scholar
• HOFFMAN SJ, LOOKER DL, ROEHRICH JM et al.: Expres-sion of fully functional tetrameric human hemoglobin in Escherichia coli. Proc. Natl. Acad. Sci. USA (1990) 87:8521–8525.
   PubMed Web of Science ®Google Scholar
• WAGENBACH M, O'ROURKE K, VITEZ L, WIECZOREK A,HOFFMAN S, DURFEE S: Synthesis of wild type and mutant human hemoglobins in Saccharomyces cerevisiae. Biotechnology (1991) 9:57–61.
   PubMed Web of Science ®Google Scholar
• AMBERSON WR, JENNINGS JJ, RHODE CM: Clinical experience with hemoglobin-saline solutions. J Appl. Physic)]. (1949) 1:469–489.
   PubMed Web of Science ®Google Scholar
• •First published clinical study describing transfusions of haemolysate in humans.
   Google Scholar
• RABINER SF, HELBERT JR, LOPAS H, FRIEDMAN LH: Evaluation of stroma-free haemoglobin for use as a plasma expander. J Exp. Med. (1967) 126:1127–1142.
   PubMed Web of Science ®Google Scholar
• •First method of removing RBC stroma components from haemoglobin to make 'stroma-free' haemoglobin.
   Google Scholar
• BUNN HF, JANDL JH: The renal handling of hemoglobin. Trans. Assoc. Am. Physicians. (1968) 81:147–152.
   PubMedGoogle Scholar
• •First report that cross-linking haemoglobin prevents renal excretion.
   Google Scholar
• SAVITSKY JP, DOCZI J, BLACK J, ARNOLD JD: A clinical safety trial of stroma-free hemoglobin. Clin. Pharmacol. Ther. (1978) 23:73–80.
   PubMed Web of Science ®Google Scholar
• •First clinical trial with stroma-free haemoglobin.
   Google Scholar
• HESS JR, MACDONALD VW, BRINKLEY WW: Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J. Appl. Physiol. (1993) 74:1769–1778.
   PubMed Web of Science ®Google Scholar
• •US Army report of preclinical data using a cross-linked haemoglobin tetramer that prevents renal damage but causes pulmonary and systemic hypertension.
   Google Scholar
• TSAI A, KERGER H, INTAGLIETTA M: Microcirculatory consequences of blood substitution with aa-hemogl-obin. In: Blood Substitutes: Physiological Basis of Efficacy Winslow RM, Vandegriff KD, Intaglietta M (Eds.), Birkhauser, Boston, USA (1995):155–174.
   Google Scholar
• •Report showing that aa-Hb decreases functional capillary density in the microcirculation of hamsters.
   Google Scholar
• AUBUCHON JP, BIRKMEYER J, BUSCH M: Safety of the blood supply in the United States: opportunities and controversies. Ann. Intern. Med. (1997) 127:904–909.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review showing the safety of US blood supplies in 1997.
   Google Scholar
• VAUGHAN P: Creutzfeldt-Jacob disease latest unknown in struggle to restore faith in blood supply. Can. Med. J. (1996) 155:565–568.
   PubMed Web of Science ®Google Scholar
• LINDEN J, TOURAULT M, SCRIBNER C: Decrease in frequency of transfusion fatalities. Transfusion (1997) 37:243–244.
   PubMed Web of Science ®Google Scholar
• GOODNOUGH LT, BRECHER ME, KANTER MH, AUBUCHON JP: Blood transfusion. N Engl. J. Med. (1999) 340:438–447.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review on the use of blood and trends in blood collection in the US.
   Google Scholar
• WALLACE EL, CHURCHILL WH, SURGENOR DM, CHO GS, MCGURK S: Collection and transfusion of blood and blood components in the United States, 1994. Transfu-sion (1998) 38:625–636.
   PubMed Web of Science ®Google Scholar
• VAMVAKAS E: Epidemiology of red blood cell utiliza-tion. Trans. Med. Rev. (1996) 10:44–61.
   PubMed Web of Science ®Google Scholar
• HAGER S, GONZALES A, GONZALES M, WINSLOW R: Erythropoietin response to blood substitutes: a model for tissue hypoxia. Blood (1996) 88:184.
   PubMedGoogle Scholar
• CHATTERJEE R, WELTY EV, WALDER RY et al.: Isolation and characterization of a new hemoglobin derivative crosslinked between the alpha chains (lysine 99 04_4 lysine 99 a2). J Biol. Chem. (1986) 261:9929–9937.
   PubMed Web of Science ®Google Scholar
• SLOAN EP, KOENIGSBERG M, GENS D, CIPOLLE M, RUNGE J, MALLORY MNRG: Diaspirin cross-linked hemoglobin (DCLI1b) in the treatment of severe traumatic hemorrhagic shock. JAMA (1999) 282: 1857-1864.
   Google Scholar
• ••Detailed description of the US Phase III trauma trial thatcaused termination of Baxter's HemAssistTM program.
   Google Scholar
• BAXTER HEALTHCARE LTD: Baxter to focus on next-generation oxygen-carrying therapeutics; decision will end clinical development of first-generation programs. (1998).
   Google Scholar
• LOOKER D, ABBOTT-BROWN D, COZART P et al: A human recombinant haemoglobin. Nature (1992) 356:258–260.
   PubMed Web of Science ®Google Scholar
• •First description of recombinant expression of 'dia' haemoglobin in E. coli for clinical development.
   Google Scholar
• SEHGAL LR, GOULD SA, ROSEN AL, SEHGAL HL, MOSS GS: Polymerized pyridoxylated hemoglobin: A red cell substitute with normal oxygen capacity. Surgery (1984) 95:433–438.
   PubMed Web of Science ®Google Scholar
• LEER, ATSUMI N, JACOBS EE, AUSTEN WG, VLAHAKES GJ: Ultrapure, stroma-free, polymerized bovine hemoglobin solution: evaluation of renal toxicity. J. Surg. Res. (1989) 47:407–411.
   PubMed Web of Science ®Google Scholar
• FRATANTONI J: Demonstration of the efficacy of a therapeutic agent. In: Blood Substitutes: Physiological Basis of Efficacy Winslow RM, Vandegriff KD, Intaglietta M (Eds.), Birkhauser, Boston, USA (1995)20–24.
   Google Scholar
• PRZYBELSKI RJ, DAILY E, BURRIS DG et al: Phase I study of the safety and pharmacologic effects of diaspirin crosslinked hemoglobin solution (DCLHb). Grit. Care Med. (1996) 24:1993–2000.
   PubMed Web of Science ®Google Scholar
• PRZYBELSKI RJ, DAILY E, BIRNBAUM M: The pressor effect of hemoglobin - good or bad? In: Advances in Blood Substitutes: Industrial Opportunities and Medical Challenges. Winslow RM, Vandegriff KD, Intaglietta M (Eds.), Birkhauser, Boston, USA (1997):71–90.
   Google Scholar
• GARRIOCH M, LARBUISSON R, BRICHANT J, LAMY M, DAILY E, PRZYBELSKI RJ: The hemodynamic effects of diaspirin cross-linked hemoglobin (DCLHb) in the operative setting. Grit. Care Med. (1996) 24:A39.
   Google Scholar
• RHEA G, BODENHAM AR, MALLICK A, DAILY E, PRZYBELSKI RJ: Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb) as a vasopressor in critically ill patients. Grit. Care Med. (1997) 25:1480–1488.
   PubMed Web of Science ®Google Scholar
• SAXENA R, WIJNHOUD AD, CARTON H eta].: Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke (1999) 30 :993–996.
   Google Scholar
• LAMY M: Clinical benefits of DCLHb following cardiac surgery. Eur. Soc. Inten. Care Med. (1997).
   Google Scholar
• HECKBERT S, VEDDER N, HOFFMAN W et al.: Outcome after hemorrhagic shock in trauma patients. J. Trauma (1998) 45:545–549.
   PubMed Web of Science ®Google Scholar
• BIROS M, RUNGE J, LEWIS R, DOHERTY C: Emergency medicine and the development of the Food and Drug Administration's final rule on informed consent in emergency research circumstances. Acad. Em erg. Med. (1998) 5:359–368.
   PubMed Web of Science ®Google Scholar
• DOHERTY DH, DOYLE MP, CURRY SR et al.: Rate of reaction with nitric oxide determines the hyperten-sive effect of cell-free hemoglobin. Nature Biotech. (1998) 16:672–676.
   PubMed Web of Science ®Google Scholar
• •Study showing correlation with recombinant haemoglobins between rates of NO binding and effects on blood pressure.
   Google Scholar
• GERBER M: Current issues in blood substitutes.Research and Development Symposia. San Diego, USA (1994).
   Google Scholar
• MURRAY JA, LEDLOW A, LAUNSPACH J, EVANS D, LOVEDAY M, CONKLIN JL: The effects of recombinant human hemoglobin on esophageal motor function in humans. Gastroenterology (1995) 109:1241–1248.
   PubMed Web of Science ®Google Scholar
• •Imaging analysis of haemoglobin-induced oesophageal peristalsis.
   Google Scholar
• GOULD S, MOORE E, MOORE F et al: Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery. J. Trauma (1997) 43:325–331.
   PubMed Web of Science ®Google Scholar
• •Early report of PolyHemeTM for blood replacement in trauma and emergency surgery.
   Google Scholar
• GOULD S, MOORE E, HOYT D et al: The first random-ized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am. Goff Stag. (1998) 187:113–120.
   Web of Science ®Google Scholar
• HUGHES GS, ANTAL EJ, LOCKER PK, FRANCOM SF, ADAMS WJ, JACOBS EE: Physiology and pharmacoki-netics of a novel hemoglobin-based oxygen carrier in humans. Grit. Care Med. (1996) 24:756–764.
   PubMed Web of Science ®Google Scholar
• KASPER S, WALTER M, GRUNE F, BISCHOFF A, ERASMI H, BUZELLO W: Effects of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth. Analg. (1996) 83:921–927.
   PubMed Web of Science ®Google Scholar
• HUGHES GS, FRANCOM SF, ANTAL EJ et al.: Hematologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects. J. Lab. Clin. Med. (1995) 126:444–451.
   PubMed Web of Science ®Google Scholar
• GONZALEZ P, HACKNEY A, JONES S et al.: A Phase VIIstudy of polymerized bovine hemoglobin in adult patients with sickle cell disease not in crisis at the time of study. J. Invest. Med. (1997) 45:258–264.
   PubMed Web of Science ®Google Scholar
• WONG L, ER S, CHRISTOFF B, CARMICHAEL F: Hemolink-induced effects on intestinal motor function and attenuation of these effects by selected agents. Artif Cells Blood Substit. Immobil. Biotech. (1998) 26:5–6.
   Google Scholar
• COHN S: Blood substitutes. NewHorizons (1999) 7:54–60.
   Google Scholar
• WINSLOW RM, GONZALES A, GONZALES ML et al.: Vascular resistance and the efficacy of red cell substi-tutes in a rat hemorrhage model. J. Appl. Physiol. (1998) 85:993–1003.
   PubMed Web of Science ®Google Scholar
• •Preclinical evaluation of different types of modified haemoglobins showing differences in effects of systemic vascular resistance and relation to survival.
   Google Scholar
• CARON A, MENU P, FAIVRE-FIORINA B, LABRUDE P, ALAYASH Al, VIGNERON C: Cardiovascular and hemorheological effects of dextran-conjugated hemoglobin, aa-crosslinked hemoglobin and o-raffinose polymerized hemoglobin in hemodiluted rabbits. J. Appl. Physiol. (1999) 86:541–548.
   PubMed Web of Science ®Google Scholar
• SAKAI H, HARA H, YUASA M et al.: Molecular dimensionsand Hb-based 02 carriers determine constriction of resistance arteries and hypertension. Am J. Physiol (2000). (In Press).
   Google Scholar
• SCHULTZ SC, HAMILTON IN, MALCOLM DS: Use of base deficit to compare resuscitation with lactated Ringer's solution, Haemaccel, whole blood and diaspirin cross-linked hemoglobin following hemorrhage in rats. J. Trauma (1993) 35:619–626.
   PubMed Web of Science ®Google Scholar
• COHN S, FARRELL T: Diaspirin cross-linked hemoglobin resuscitation of hemorrhage. J. Trauma (1995) 39:210–216.
   PubMed Web of Science ®Google Scholar
• SCHULTZ S, POWELL C, BURRIS D, NGUYEN H, JAFFIN J, MALCOLM DS: The efficacy of diaspirin crosslinked hemoglobin solution resuscitation in a model of uncontrolled hemorrhage. j Trauma (1994) 37:408–412.
   PubMed Web of Science ®Google Scholar
• WINSLOW R: aa-Crosslinked hemoglobin: was failure predicted by preclinical testing? Vox Sang. (2000) . (In Press).
   Google Scholar
• •Review of preclinical data with aa-Hb and its ability to predict the failure of HemAssistml.
   Google Scholar
• HESS J, RIESS R: Resuscitation and the limited utility of the present generation of blood substitutes. Transfus. Med. Rev. (1996) 10:276–285.
   PubMed Web of Science ®Google Scholar
• POHL U, HERLAN K, HUANG A, BASSENGE E: EDRF-mediated shear-induced dilation opposes myogenic vasoconstriction in small rabbit arteries. Am. J. Physic]. (1991) 261:H2016–H2023.
   Web of Science ®Google Scholar
• FRANGOS JA, ESKIN SG, McINTIRE LV, IVES CL: Flow effects on prostacyclin production in cultured human endothelial cells. Science (1985) 227:1477–1479.
   PubMed Web of Science ®Google Scholar
• HOMER LD, WEATHERSBY PK, KIESOW LA: Oxygen gradients between red blood cells in the microcircula-tion. Microvasc. Res. (1981) 22:308–323.
   PubMed Web of Science ®Google Scholar
• FEDERSPIEL W, POPEL A: A theoretical analysis of the effect of the particulate nature of blood on oxygen release in capillaries. Micro. Vasc. Res. (1986) 32:164–189.
   PubMed Web of Science ®Google Scholar
• PAGE TC, LIGHT WR, McKAY CB, HELLUMS JD: Oxygen transport by erythrocyte/hemoglobin solution mixtures in an in vitro capillary as a model of hemoglobin-based oxygen carrier performance. Microvasc. Res. (1998) 55:54–64.
   PubMed Web of Science ®Google Scholar
• •Study using an artificial capillary that shows facilitated diffusion 02 by of cell-free haemoglobin solutions.
   Google Scholar
• LINDBOM L, TUMA RF, ARFORS KE: Influence of oxygen on perfused capillary density and capillary red cell velocity in rabbit skeletal muscle. Microvas. Res. (1980) 19:197–208.
   PubMed Web of Science ®Google Scholar
• •Study in the microcirculation of rabbits showing autoregula-tory vasoconstriction under conditions of hyperoxia.
   Google Scholar
• VANDEGRIFF KD, WINSLOW RM: A theoretical analysis of oxygen transport: a new strategy for the design of hemoglobin-based red cell substitutes. In: Blood Substi-tutes: Physiological Basis of Efficacy. Winslow RM, Vandegriff KD, Intaglietta M (Eds.), Birkhauser, Boston, USA (1995):143–154.
   Google Scholar
• WINSLOW RM, VANDEGRIFF KD: Hemoglobin oxygen affinity and the design of red cell substitutes. In: Blood Substitutes: Industrial Opportunities and Medical Challenges. Winslow RM, Vandegriff KD, Intaglietta M (Eds.), Birkhauser, Boston, USA (1997):167–188.
   Google Scholar
• LOSCALZO J: Nitric oxide binding and the adverseeffects of cell-free hemoglobins: what makes us different from earthworms. J. Lab. Clin. Med. (1997) 129:580–583.
   PubMedGoogle Scholar
• ROHLFS RJ, BRUNER E, CHIU A et al.: Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide. j Biol. Chem. (1998) 273:12128–12134.
   PubMed Web of Science ®Google Scholar
• •First study to demonstrate that different types of haemoglobin modification induce different blood pressure effects that are not related to NO reactivity.
   Google Scholar
• BALDWIN AL: Modified hemoglobins produce venular interendothelial gaps and albumin leakage in the rat mesentery. Am. J. Physiol (1999) 277:H650–H659.
   PubMed Web of Science ®Google Scholar
• CENTRE FOR BIOLOGICS RESEARCH AND EVALUATION:Points to consider in the safety and evaluation of hemoglobin-based oxygen carriers. Transfusion (1991) 31:369–371.
   PubMed Web of Science ®Google Scholar
• •FDA recommendations on safety and efficacy end points for haemoglobin-based oxygen carriers.
   Google Scholar
• CENTRE FOR BIOLOGICS RESEARCH AND EVALUATION: Points to consider on efficacy evaluation of hemoglo-bin- and perfluorocarbon-based oxygen carriers. Transfusion (1994) 34:712–713.
   PubMed Web of Science ®Google Scholar
• •FDA recommendations on safety and efficacy end points for haemoglobin-based oxygen carriers.
   Google Scholar
• Pivotal clinical trials of blood substitutes begin.Biotech. News (1995) 15:2–6.
   Google Scholar
• STOVER 8z ASSOCIATES L: Anew generation of oxygentherapeutics. Stamford, CT, USA (1996).
   Google Scholar
• www.fda.gov/cber/minutes/oxygen092799.pdf Workshop on criteria for safety and evaluation of oxygen therapeutics as substitutes. (1999):23–38.
   Google Scholar
• www.fda.gov/cber/minutes/oxygen092799.pdf Workshop on criteria for safety and evaluation of oxygen therapeutics as substitutes. (1999):8–23.
   Google Scholar
• www.fda.gov/cber/minutes/oxygen092799.pdf Workshop on criteria for safety and evaluation of oxygen therapeutics as substitutes. (1999)59–75. efficacy red cell efficacy red cell efficacy red cell
   Google Scholar
• www.fda.govicberiminutesioxygen092799.pdf Workshop on criteria for safety and efficacy evaluation of oxygen therapeutics as red cell substitutes. (1999):114–130.
   Google Scholar
• www.fda.govicberiminutesioxygen092799.pdf Workshop on criteria for safety and efficacy evaluation of oxygen therapeutics as red cell substitutes. (1999):91–104.
   Google Scholar
• www.fda.govicberiminutesioxygen092799.pdf Workshop on criteria for safety and efficacy evaluation of oxygen therapeutics as red cell substitutes. (1999):104–114.
   Google Scholar
• www.fda.govicberiminutesioxygen092799.pdf Workshop on criteria for safety and efficacy evaluation of oxygen therapeutics as red cell substitutes. (1999)39–54.
   Google Scholar